Memphasys (ASX:MEM) Secures A Felix™ Commercialisation Agreement in Poland

Sonal Goyal

05 August 2026 10:34 AM AEST

Memphasys (ASX:MEM) Secures A Felix™ Commercialisation Agreement in Poland

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Memphasys (ASX:MEM) has signed an exclusive Felix™ System commercialisation agreement with TK Biotech in Poland.
The agreement includes minimum contracted purchases valued at approximately A$350,000 over a two-year commercial period.
Poland becomes the third European market with Felix™ commercial sales or agreements following Italy and the United Kingdom.
The partnership provides a pathway from initial evaluation activities to recurring quarterly product purchases.

Memphasys (ASX:MEM) has announced the expansion of its European commercial strategy through an exclusive commercialisation agreement for its Felix™ System in Poland. The agreement with Warsaw-based TK Biotech represents another step in the company’s international roll-out following regulatory approval in Europe.

The partnership introduces Felix™ to Poland’s growing assisted reproductive technology sector and establishes a structured pathway from initial product evaluation to ongoing commercial supply. The agreement includes minimum purchase commitments valued at approximately €212,000, equivalent to around A$350,000, across the two-year commercial term.

Felix™ Agreement Expands European Market Presence

Under the agreement, TK Biotech has been appointed as the exclusive commercialisation partner for Felix™ in Poland, subject to minimum purchase commitments and performance obligations.

The arrangement begins with a three-month evaluation and market introduction period, during which TK Biotech will support product demonstrations, customer training and engagement with fertility clinics. Following successful completion of this phase, contracted quarterly purchase commitments will begin.

The initial evaluation order is expected to be invoiced during the September 2026 quarter, with the first minimum quarterly purchase order anticipated in the December 2026 quarter. Revenue will be recognised as products are supplied and invoiced in accordance with agreed commercial terms.

Growing IVF Market Creates Commercial Opportunity

Poland’s fertility treatment sector has experienced increased accessibility following the introduction of a government-funded IVF program in 2024. The program has expanded access to assisted reproductive services through participating fertility clinics across the country.

This market environment provides opportunities for technologies designed to improve laboratory workflows and support fertility treatment outcomes. Memphasys believes Felix™ can address demand for advanced sperm preparation solutions within IVF laboratories.

The company’s commercial model focuses on working with established local distributors to support product education, clinical engagement and adoption among fertility specialists.

TK Biotech Partnership Supports Local Market Entry

TK Biotech, based in Warsaw, operates as a distributor of laboratory equipment, diagnostic products and reagents across research, healthcare and biotechnology sectors. The company has an established IVF-focused business and relationships with fertility clinics throughout Poland.

The distributor’s scientific expertise, technical support capabilities and existing assisted reproduction portfolio provide a platform for introducing Felix™ to local IVF providers.

TK Biotech will manage importer and distributor requirements while supporting clinic engagement, product demonstrations, onboarding and customer support activities. Memphasys will provide technical training, approved marketing resources and support for selected educational and clinical activities.

Felix™ Technology and Commercial Strategy

The Felix™ System is designed as a sperm separation technology for assisted reproduction procedures. The platform combines electrophoresis and size-exclusion membrane technology to isolate selected sperm cells through a standardised laboratory process.

Memphasys’ commercial strategy focuses on developing recurring revenue streams through distributor partnerships, direct sales channels and ongoing cartridge consumption associated with Felix™ usage.

The company continues to target IVF markets where laboratories are seeking technologies that can support workflow efficiency and reproductive treatment processes.

European Expansion and Future Growth Plans

The Poland agreement follows Felix™ commercial activity in Italy and the United Kingdom, making Poland the third European market where the technology has secured commercial sales or a commercialisation arrangement.

Memphasys is continuing discussions with additional prospective partners and IVF groups following interest generated through industry engagement, including participation at ESHRE 2026.

The company has also appointed a Director of Commercial Operations – Europe to support partner onboarding, customer relationships and the development of its European commercial network.

Conclusion

Memphasys’ Felix™ agreement in Poland represents a further step in expanding its European commercial footprint and establishing distribution channels for its reproductive biotechnology platform. The partnership with TK Biotech provides a structured route from product evaluation to recurring purchases while positioning Felix™ within a growing IVF market. Continued partner development and market adoption will shape the company’s progress in expanding its international presence.

FAQs

Q: What is the value of Memphasys’ Felix™ agreement in Poland?

A:The agreement includes minimum contracted purchases valued at approximately A$350,000 over the two-year commercial period.

Q: Who is Memphasys partnering with in Poland?

A:Memphasys has appointed TK Biotech Sp. z o.o. as the exclusive commercialisation partner for Felix™ in Poland.

Q: What is the Felix™ System used for?

A:Felix™ is a sperm preparation technology designed for use in assisted reproductive technology procedures, including IVF laboratory workflows.

Q: How will the Poland agreement progress commercially?

A:The agreement begins with a three-month evaluation and market introduction period, followed by contracted quarterly purchase commitments.

Q: Which European markets have Felix™ secured commercial agreements in?

A:Felix™ has secured commercial sales or agreements in Poland, Italy and the United Kingdom following European regulatory approval.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.